FDA Approved Increased Doses of The Vaccine For Certain Immunocompromised Individuals

The FDA amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech & the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals.
 
WATERTOWN, Mass. - Aug. 17, 2021 - PRLog -- Few days ago, the FDA amended the emergency use authorizations (EUAs) for both the Pfizer-BioNTech & the Moderna COVID-19 Vaccine to allow for the use of an additional dose in certain immunocompromised individuals, specifically, solid organ transplant recipients or those who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise. Today's action does not apply to people who are not immunocompromised.

People who are immunocompromised in a manner similar to those who have undergone solid organ transplantation have a reduced ability to fight infections and other diseases, and they are especially vulnerable to infections, including COVID-19. The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna Vaccines in these individuals and determined that the administration of third vaccine doses may increase protection in this population. These patients should be counseled to maintain physical precautions to help prevent COVID-19. In addition, close contacts of immunocompromised persons should get vaccinated, as appropriate for their health status, to provide increased protection to their loved ones.

The FDA has authorized monoclonal antibody treatments for emergency use during this public health emergency for adults and pediatric patients (ages 12 and older weighing at least 40 kilograms or about 88 pounds) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID-19 and/or hospitalization.

The Pfizer-BioNTech COVID-19 Vaccine is currently authorized for emergency use in individuals ages 12 and older, and the Moderna COVID-19 Vaccine is authorized for emergency use in individuals ages 18 and older. Both vaccines are administered as a series of two shots: the Pfizer-BioNTech COVID-19 Vaccine is administered three weeks apart, and the Moderna COVID-19 Vaccine is administered one month apart. The authorizations for these vaccines have been amended to allow for an additional, or third, dose to be administered at least 28 days following the two-dose regimen of the same vaccine to individuals 18 years of age or older (ages 12 or older for Pfizer-BioNTech) who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

As a reliable worldwide supplier of PEG & ADC linkers, Biochempeg supplies a variety of high purity PEG derivatives, PEG linkers and ADC linkers to empower drug research & development. We can produce and provide the some PEG products used in COVID-19 vaccines (https://www.biochempeg.com/product/527/).

Contact
Sonila Li
***@biochempeg.com
End
Email:***@biochempeg.com
Posted By:***@biochempeg.com Email Verified
Tags:Covid-19 Vaccine
Industry:Business
Location:Watertown - Massachusetts - United States
Subject:Products
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Biochempeg Scientific Inc. PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share